NGR 6172 Advanced Pharmacology – Diabetes Medications & Insulin Therapy – 32 Questions

This document contains 32 verified exam-style questions and answers focused exclusively on diabetes pharmacology for NGR 6172 Advanced Pharmacology. It provides detailed review of mechanisms of action (MOA), side effects, hypoglycemia risk, and insulin onset and duration profiles for major antidiabetic drug classes including insulin, sulfonylureas, biguanides (metformin), thiazolidinediones (Actos), meglitinides, alpha-glucosidase inhibitors, and incretin-based therapies. The material is organized in a concise question-and-answer format to support rapid memorization and clinical exam preparation. It covers high-yield pharmacotherapeutic concepts such as which agents directly cause hypoglycemia, insulin classifications (rapid, short, intermediate, long-acting, and combination 70/30 formulations), duration of action comparisons, and key adverse effects including lactic acidosis, CHF risk, weight gain, B12 deficiency, and hypoglycemia patterns. This content aligns with Pharmacotherapeutics for Advanced Practice Nurse Prescribers and other core graduate-level APRN pharmacology textbooks used in nurse practitioner and CRNA programs. This resource is suitable for the following courses and programs: NGR 6172 Advanced Pharmacology Graduate Nursing Pharmacology APRN Core Pharmacotherapeutics Nurse Practitioner Clinical Pharmacology CRNA Pharmacology This document is especially beneficial for: Family Nurse Practitioner (FNP) students Adult-Gerontology NP students Acute Care NP students Women’s Health NP students CRNA students Graduate nursing students preparing for pharmacology exams APRN candidates reviewing diabetes medication management Keywords: NGR 6172 diabetes drugs, advanced pharmacology diabetes, insulin mechanism of action, metformin MOA, sulfonylureas side effects, thiazolidinediones CHF risk, incretin therapy, meglitinides, alpha glucosidase inhibitors, hypoglycemia risk agents, insulin onset duration, rapid acting insulin, long acting insulin, 70 30 insulin, APRN pharmacology